Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis

SARS-CoV-2 has had a great impact on world health, patients on hemodialysis have a higher rate of infection and death due to COVID-19. Vaccination is important to control infection and improve the prognosis of infected patients. To describe the efficacy of vaccination against SARS-CoV-2 in Chilean p...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2023-12, Vol.19 (1), p.2173904-2173904
Main Authors: Sanhueza, María E., San Martín, Pamela, Brantes, Loreto, Caro, Sylvia, Carrasco, Guillermo, Machuca, Eduardo
Format: Article
Language:English
Subjects:
Aged
Coronavirus
COVID-19 - prevention & control
COVID-19 vaccines
efficacy
hemodialysis
Humans
Middle Aged
Renal Dialysis
Renal Insufficiency, Chronic
SARS-CoV-2
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS-CoV-2 has had a great impact on world health, patients on hemodialysis have a higher rate of infection and death due to COVID-19. Vaccination is important to control infection and improve the prognosis of infected patients. To describe the efficacy of vaccination against SARS-CoV-2 in Chilean patients on hemodialysis during the year 2021. Retrospective observational study. A total of 9,712 clinical records were reviewed. Data were presented as summary measures. Fisher's exact test, Mann-Whitney U test, and multivariate logistic regression were used for the analysis. Risk and survival analysis were calculated, considering a statistical significance of less than 0.05. The average age of the patients attended was 61.5 ± 14.6 years. Average time on dialysis 67.6 months and 35.0% diabetic. 93.2% of patients were vaccinated against SARS-CoV-2, 70.7% of them received booster doses. The risk of infection was higher for those who received one or no dose, compared to those who received booster doses against SARS-CoV-2: OR = 252.46 [165.13; 401.57]. Of the infected patients, 15.7% died from COVID-19. The risk of death was higher in unvaccinated or single-dose patients compared to those vaccinated with two doses: OR = 2.64 [2.23; 3.12]. Patients with two doses and a booster had a longer survival compared to those who received one or no dose of vaccination against SARS-CoV-2 (p 
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2023.2173904